FY2024 EPS Estimates for Imunon Boosted by Zacks Small Cap

Imunon, Inc. (NASDAQ:IMNN) – Zacks Small Cap boosted their FY2024 earnings per share (EPS) estimates for Imunon in a report released on Monday, November 11th. Zacks Small Cap analyst D. Bautz now anticipates that the company will earn ($1.74) per share for the year, up from their previous forecast of ($1.90). The consensus estimate for Imunon’s current full-year earnings is ($1.68) per share.

Imunon (NASDAQ:IMNN) last posted its earnings results on Wednesday, August 14th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.04.

Other equities analysts have also issued reports about the stock. HC Wainwright reduced their target price on shares of Imunon from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Monday. EF Hutton Acquisition Co. I upgraded Imunon to a “strong-buy” rating in a report on Monday, September 23rd.

Imunon Stock Performance

Shares of IMNN opened at $0.75 on Wednesday. The firm’s 50 day moving average price is $1.00 and its two-hundred day moving average price is $1.19. Imunon has a twelve month low of $0.48 and a twelve month high of $3.65. The firm has a market cap of $44.84 million, a P/E ratio of -0.40 and a beta of 2.14.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.